December 3, 2020 -- Inovio has brought Belgium-based Kaneka Eurogentec on board a global consortium of companies that will be manufacturing its DNA COVID-19 vaccine INO-4800, which is in phase II/III development.
Kaneka Eurogentec, an affiliate of Kaneka Corporation of Tokyo, joins a manufacturing consortium that includes Thermo Fisher Scientific, Richter-Helm BioLogics, and Ology Biosciences. Terms of the deal with Kaneka were not disclosed.
Inovio said that it is planning to produce hundreds of millions of doses of the vaccine worldwide through third-party partners. The investigational vaccine, which is given in two doses, does not require freezing for transport or storage and Inovio said that it is stable at room temperature for up to one year. Development is being funded by the U.S. Department of Defense.